Clinical trial · Research · 23 Oct 2026
Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
Source: ScienceDaily
What the research found
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.
Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.
More research news
- In mice, fear made hippocampal maps of a safe place and a dangerous place overlap
- In pregnant mice, immune activation at day 12.5 lined up with placental injury and autism-like traits in male fetuses only
- Support cells in brain tissue from 73 people with Parkinson's showed sex differences in energy-gene and myelin-gene activity
- In 10,362 adults, night-to-night swings in sleep timing lined up with a higher risk of serious cardiovascular events
- In a U.S. telephone survey of 442,906 adults, reported cannabis use lined up with higher odds of cardiovascular disease, especially stroke